RELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC

Simple item page
dc.contributor.authorAix, S.
dc.contributor.authorNovello, S.
dc.contributor.authorGaron, E.
dc.contributor.authorNakagawa, K.
dc.contributor.authorNadal, E.
dc.contributor.authorMoro-Sibilot, D.
dc.contributor.authorAlonso Garcia, M.
dc.contributor.authorFabre, E.
dc.contributor.authorFrimodt-Moller, B.
dc.contributor.authorZimmermann, A.
dc.contributor.authorVisseren-Grul, C.
dc.contributor.authorReck, M.
dc.contributor.authoraffiliation[Aix, S.] Hosp Doce Octubre Carretera Andalucia, Madrid, Spain
dc.contributor.authoraffiliation[Novello, S.] Univ Turin, Turin, Italy
dc.contributor.authoraffiliation[Garon, E.] Univ Calif Los Angeles, David Geffen Sch Med, Translat Res Oncol Us Network, Los Angeles, CA 90095 USA
dc.contributor.authoraffiliation[Nakagawa, K.] Kindai Univ, Fac Med, Osaka, Japan
dc.contributor.authoraffiliation[Nadal, E.] Inst Catala Oncol, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Moro-Sibilot, D.] CHU Grenoble, La Tronche, France
dc.contributor.authoraffiliation[Alonso Garcia, M.] Hosp Virgen Del Rocio, Seville, Spain
dc.contributor.authoraffiliation[Fabre, E.] Hop Europeen Georges Pompidou, Ghu Paris Ouest, Serv Oncol Thorac, Paris, France
dc.contributor.authoraffiliation[Frimodt-Moller, B.] Eli Lilly & Co, Herlev, Denmark
dc.contributor.authoraffiliation[Zimmermann, A.] Eli Lilly & Co, Indianapolis, IN 46285 USA
dc.contributor.authoraffiliation[Visseren-Grul, C.] Eli Lilly, Oncol, Utrecht, Netherlands
dc.contributor.authoraffiliation[Reck, M.] Lung Clin Grosshansdorf, Airway Res Ctr North Arcn, Grosshansdorf, Germany
dc.contributor.authoraffiliation[Reck, M.] German Ctr Lung Res Dzl, Grosshansdorf, Germany
dc.date.accessioned2025-01-07T15:34:30Z
dc.date.available2025-01-07T15:34:30Z
dc.date.issued2019-10-01
dc.identifier.doi10.1016/j.jtho.2019.08.1317
dc.identifier.essn1556-1380
dc.identifier.issn1556-0864
dc.identifier.unpaywallURLhttp://www.jto.org/article/S1556086419320003/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27251
dc.identifier.wosID492162203232
dc.issue.number10
dc.issue.numberS
dc.journal.titleJournal of thoracic oncology
dc.journal.titleabbreviationJ. thorac. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS625-S625
dc.publisherElsevier science inc
dc.rights.accessRightsopen access
dc.subjectEU/US subset
dc.subjectEGFR-mutation positive NSCLC
dc.subjectRamucirumab
dc.titleRELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number14
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía